916 Shares of IDEXX Laboratories, Inc. $IDXX Purchased by Legacy Wealth Management LLC MS

Legacy Wealth Management LLC MS purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 916 shares of the company’s stock, valued at approximately $478,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Gerber Kawasaki Wealth & Investment Management raised its stake in shares of IDEXX Laboratories by 21.7% during the third quarter. Gerber Kawasaki Wealth & Investment Management now owns 572 shares of the company’s stock worth $299,000 after buying an additional 102 shares during the last quarter. Greenfield Seitz Capital Management LLC lifted its holdings in IDEXX Laboratories by 1.2% in the third quarter. Greenfield Seitz Capital Management LLC now owns 4,925 shares of the company’s stock valued at $2,572,000 after buying an additional 59 shares during the period. Keeler Thomas Management LLC bought a new position in IDEXX Laboratories in the third quarter valued at approximately $925,000. Bell Investment Advisors Inc boosted its stake in IDEXX Laboratories by 45.5% in the third quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock valued at $33,000 after acquiring an additional 20 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in IDEXX Laboratories in the third quarter valued at approximately $30,405,000. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Citigroup lifted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Leerink Partners cut their price target on IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Jefferies Financial Group cut their price target on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a research note on Tuesday, October 20th. UBS Group restated a “neutral” rating on shares of IDEXX Laboratories in a research report on Tuesday. Finally, The Goldman Sachs Group initiated coverage on IDEXX Laboratories in a research note on Friday, October 16th. They set a “buy” rating and a $740.00 price objective for the company. Eight analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $721.67.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $671.64 on Tuesday. The company has a market capitalization of $52.91 billion, a price-to-earnings ratio of 47.23 and a beta of 1.55. The firm’s 50 day simple moving average is $536.56 and its 200 day simple moving average is $573.88. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a fifty-two week low of $500.61 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.71 by $0.25. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the firm earned $3.22 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Trending Headlines about IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates. IDEXX reported adjusted earnings of approximately $3.96–$3.98 per share versus the $3.71 consensus estimate. Revenue rose about 10% year over year to $1.21 billion, exceeding expectations of roughly $1.19 billion. IDEXX Laboratories Q3 earnings report
• Positive Sentiment: Recurring diagnostics remained the key growth engine. Recurring diagnostic revenue to veterinarians increased about 11%, demonstrating continued demand for IDEXX’s testing platforms and supporting the company’s earnings growth despite softer veterinary visit trends. IDEXX raises forecast
• Positive Sentiment: Management raised its full-year 2026 earnings and revenue guidance. The revised outlook suggests that IDEXX expects diagnostics growth, operating performance and customer adoption of its offerings to offset weakness in veterinary visit volumes. The guidance increase was the primary catalyst behind the strong stock reaction. IDEXX revises 2026 earnings guidance
• Neutral Sentiment: The earnings call reinforced a favorable long-term growth narrative. Management highlighted continued expansion in diagnostics, recurring revenue and productivity initiatives, which may support durable growth but also leaves the stock reliant on sustained premium valuation expectations. IDEXX Laboratories earnings call highlights
• Negative Sentiment: Margin trends and veterinary demand remain risks. Some reports noted that the higher profit forecast was not driven by stronger testing demand, while the margin outlook softened. Weak veterinary visits could pressure near-term volume growth if diagnostics expansion does not continue. IDEXX sales and margin outlook

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.